Amneal Pharmaceuticals, Inc. 2DT.F Stock
Amneal Pharmaceuticals, Inc. Price Chart
Amneal Pharmaceuticals, Inc. 2DT.F Financial and Trading Overview
Amneal Pharmaceuticals, Inc. stock price | 5.25 EUR |
Previous Close | 2.44 EUR |
Open | 2.44 EUR |
Bid | 2.42 EUR x 0 |
Ask | 2.5 EUR x 0 |
Day's Range | 2.44 - 2.44 EUR |
52 Week Range | 1.16 - 3.5 EUR |
Volume | 5 EUR |
Avg. Volume | 0 EUR |
Market Cap | 801.44M EUR |
Beta (5Y Monthly) | 1.32183 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.45 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.33 EUR |
2DT.F Valuation Measures
Enterprise Value | 2.94B EUR |
Trailing P/E | N/A |
Forward P/E | 2.6813188 |
PEG Ratio (5 yr expected) | -0.52 |
Price/Sales (ttm) | 0.35271263 |
Price/Book (mrq) | 1.2708334 |
Enterprise Value/Revenue | 1.293 |
Enterprise Value/EBITDA | 6.302 |
Trading Information
Amneal Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.32183 |
52-Week Change | -13.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.5 EUR |
52 Week Low | 1.16 EUR |
50-Day Moving Average | 1.69 EUR |
200-Day Moving Average | 1.98 EUR |
2DT.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 153.34M |
Float | 102.48M |
Short Ratio | N/A |
% Held by Insiders | 10.87% |
% Held by Institutions | 64.00% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -5.93% |
Operating Margin (ttm) | 9.93% |
Gross Margin | 35.43% |
EBITDA Margin | 20.51% |
Management Effectiveness
Return on Assets (ttm) | 3.75% |
Return on Equity (ttm) | -88.19% |
Income Statement
Revenue (ttm) | 2.27B EUR |
Revenue Per Share (ttm) | 15 EUR |
Quarterly Revenue Growth (yoy) | 12.00% |
Gross Profit (ttm) | 791.46M EUR |
EBITDA | 466.18M EUR |
Net Income Avi to Common (ttm) | -134772992 EUR |
Diluted EPS (ttm) | -0.83 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 147.98M EUR |
Total Cash Per Share (mrq) | 0.97 EUR |
Total Debt (mrq) | 2.85B EUR |
Total Debt/Equity (mrq) | 1759.18 EUR |
Current Ratio (mrq) | 1.858 |
Book Value Per Share (mrq) | 1.92 |
Cash Flow Statement
Operating Cash Flow (ttm) | 84.47M EUR |
Levered Free Cash Flow (ttm) | 243.78M EUR |
Profile of Amneal Pharmaceuticals, Inc.
Country | Germany |
State | NJ |
City | Bridgewater |
Address | 400 Crossing Boulevard |
ZIP | 08807 |
Phone | 908 947 3120 |
Website | https://amneal.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 7600 |
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Q&A For Amneal Pharmaceuticals, Inc. Stock
What is a current 2DT.F stock price?
Amneal Pharmaceuticals, Inc. 2DT.F stock price today per share is 5.25 EUR.
How to purchase Amneal Pharmaceuticals, Inc. stock?
You can buy 2DT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amneal Pharmaceuticals, Inc.?
The stock symbol or ticker of Amneal Pharmaceuticals, Inc. is 2DT.F.
Which industry does the Amneal Pharmaceuticals, Inc. company belong to?
The Amneal Pharmaceuticals, Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Amneal Pharmaceuticals, Inc. have in circulation?
The max supply of Amneal Pharmaceuticals, Inc. shares is 308.55M.
What is Amneal Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Amneal Pharmaceuticals, Inc. PE Ratio is now.
What was Amneal Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Amneal Pharmaceuticals, Inc. EPS is -0.45 EUR over the trailing 12 months.
Which sector does the Amneal Pharmaceuticals, Inc. company belong to?
The Amneal Pharmaceuticals, Inc. sector is Healthcare.